

Global Clinical Development Pipeline

Phase 1

Sonrotoclax ● 101/102 B-cell malignancies ● 103 AML/MDS ● 105 MM t(11;14)	BCL2i	BGB-A3055 ● 101 Solid tumors	Anti CCR8
BGB-16673 ● 102 B-cell malignancies	BTK CDAC	BGB-24714 ● 101 Solid tumors	SMAC mimetic
BGB-21447 ● 101 B-cell malignancies	next gen BCL2i	BGB-43395 ● 101/102 BC & Solid tumors	CDK4i
Tislelizumab ● 103 SubQ formulation	Anti PD1	BG-68501¹ ● 101 BC & Solid tumors	CDK2i
Ociperlimab ● 900-105 NSCLC dose confirmation ● 101 R/R DLBCL	Anti TIGIT	BG-C9074² ● 101 BC & Solid tumors	B7H4 ADC
BGB-15025 ● 101 Solid tumors	HPK1i	BGB-45035 ● 101 Immunology & Inflammation	IRAK4 CDAC
BGB-26808 ● 101 Solid tumors	HPK1i	BGB-C354 ● 101 Solid tumors	B7H3 ADC
BGB-30813 ● 101 Solid tumors	DGKζi	BGB-R046 ● 101 Solid tumors	IL-15 prodrug
		Xaluritamig⁴ ● 20180146 mCRPC	Anti STEAP1xCD3

Phase 2

Zanubrutinib ● 215 B-cell lymphoma ● 218 CD79B R/R DLBCL ● 217 Lupus nephritis	BTKi	BGB-16673 ● 101 R/R MCL, R/R CLL	BTK CDAC
Sonrotoclax ● 201 R/R MCL ● 202 R/R CLL ● 203 R/R WM	BCL2i	Blinatumomab⁴ ● 20190359 Ped. R/R BP-ALL (initiation act.)	Anti CD3xCD19
LBL-007⁵ ● 201 MSS-CRC ● 202 1L ESCC	Anti LAG3	BGB-A445 ● 201 Melanoma, UC	Anti OX40
Umbrella Studies ● LC-201 1L NSCLC ● LC-203 2L+ NSCLC ● LC-202 Neoadj NSCLC ● HNSCC-201 1L HNSCC	IO Combos	Tarlatamab⁴ ● 20230273 3L SCLC (initiation activities)	Anti DLL3xCD3

Phase 3

Zanubrutinib ● 306 TN MCL ● 308 R/R MZL, R/R FL ● 309 pMN	BTKi	Sonrotoclax ● 301 TN CLL	BCL2i
Tislelizumab ● 310 1L UBC ● 311 LA ESCC ● 314 R/R cHL	Anti PD1	Pamiparib ● 302 2L MTx gBRCAm PSOC	PARPi
Ociperlimab ● 302 1L NSCLC PDL1-high	Anti TIGIT	Zanidatamab³ ● 301 1L HER2+ GEA	Anti HER2 BsAb
Tarlatamab⁴ ● 20210004 2L SCLC ● 20200041 1L ES-SCLC ● 20230016 LS-SCLC	Anti DLL3xCD3		

Registration


Zanubrutinib ● 304 TN CLL/SLL (JP) ● 305 R/R CLL/SLL (JP) ● 302 TN WM (JP)	BTKi	Tislelizumab ● 315 Neo/adj NSCLC (CN) ● 305 1L GC/GEJC ITT (US, EU) ● 306 1L ESCC (US, EU, JP) ● 302 2L ESCC (JP)	Anti PD1
Zanidatamab³ ● 203 HER2+ 2L BTC (CN)	Anti HER2 BsAb		

Registration includes select accepted submissions

- 1) Ensem collaboration
- 2) DualityBio collaboration
- 3) Zymeworks/Jazz collaboration
- 4) Amgen collaboration
- 5) Leads Biolabs collaboration

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details.

Updated August 2024



Please see clinical trials details in a "BeiGene Q2 Clinical Trials Portfolio" presentation found on <https://ir.beigene.com>